news

Crohn’s patients achieve 65 percent clinical remission with Tremfya®

1
SHARES

At week 48 of the Phase II trial, 65 percent of patients with Crohn’s disease receiving Tremfya® achieved clinical remission.

Man clenching stomach with faded illustration of stomach

Janssen has announced topline results from the Phase II GALAXI 1 clinical trial which showed rates of clinical remission – Crohn’s Disease Activity Index [CDAI]<150 – previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with Tremfya® (guselkumab). At week 48, 65 percent of Crohn’s patients receiving Tremfya achieved clinical remission.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

GALAXI 1 is a double-blind, placebo-controlled, multicentre Phase II dose-ranging study evaluating the efficacy and safety of Tremfyain participants with moderately to severely active CD with inadequate response/intolerance to conventional therapies (corticosteroid, immunosuppressives) and/or biologics (TNF antagonists, vedolizumab).

Participants were randomised equally into five treatment arms, including treatment with Tremfya dosed at 200, 600 or 1200mg intravenously (IV) at weeks 0, 4 and 8, respectively; or treatment with the reference arm, ustekinumab, dosed at ~6mg/kg IV at week 0 and then dosed at 90 mg subcutaneously (SC) at week 8; or IV placebo. Comparison with placebo was not conducted beyond week 12.

The primary endpoint of the Phase II GALAXI 1 study is change from baseline in CDAI scores at week 12. Additional key outcomes evaluated at week 12 include clinical remission (CDAI<150), clinical response (decrease from baseline in CDAI ≥100 or CDAI<150), Patient Report Outcome (PRO)-2 remission (abdominal pain mean daily score ≤1 and mean daily stool frequency score ≤3), clinical biomarker response (clinical response and ≥50 percent reduction from baseline in C-reactive protein or fecal calprotectin), endoscopic response (≥50 percent improvement from baseline in the SES-CD), and safety in participants treated with Tremfya compared with placebo. Participants may receive treatment through five years.

Janssen previously announced week 12 interim analyses from the 48-week, double-blind, placebo-controlled, multicentre Phase II dose-ranging GALAXI 1 study. The primary endpoint of the Phase II study is change from baseline in CDAI scores at week 12 in patients treated with Tremfya compared to placebo. Overall, all Tremfya treatment groups during the 48-week treatment period in GALAXI 1 had comparable safety data, consistent with the known safety profile for Tremfya.

Tremfya is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. The drug is under investigation and not currently approved for the treatment of CD in the US.

The 48-week GALAXI 1 results mark the first long-term data evaluating Tremfya in moderately to severely active CD. Phase III clinical trials evaluating the drug for the treatment of moderately to severely active CD and moderately to severely active ulcerative colitis are ongoing and enrolling participants.

Related organisations

Related drugs

Related diseases & conditions

Share via
Share via